Rosanna Sutherby, Pharm.D.

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Cedars-Sinai was one of 12 among 172 adult transplant centers in the U.S. with a one-year patient post-transplant survival rate above the expected outcome. In 2024, the survival rate for Cedars-Sinai was 90% versus the expected rate of 68% to 83%.

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

The antibody-drug conjugate (ADC), marketed by ADC Therapeutics under the brand name Zynlonta, received accelerated approval in April 2021. Full approval is contingent upon positive results from confirmatory trials.

It is known that patients with active IBD have an increased risk of preterm birth, slowed fetal growth, low birth weight, hypertensive disease of pregnancy, and cesarean birth. On the other hand, conception during disease remission results in similar relapse rates as for people with IBD who are not pregnant.

Previous studies have found no association between vaccination and MS in adults. To evaluate the association between vaccinations and pediatric-onset MS, researchers conducted a retrospective case-control study using data from the Bavarian Association of Statutory Health Insurance Physicians database.

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

10 treatments are listed as first-line advanced therapies. Rinvoq (upadacitinib) is the only one with a clinically meaningful difference from placebo of over 20%.

The investigational Bruton’s tyrosine kinase performed well in the phase 3 HERCULES trial.

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.

Researchers say patient-reported disability can be used as a metric in outcomes-based contracts related to the care of multiple sclerosis patients.

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal complications among those treated with semaglutide, tirzepatide and other GLP-1s.

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative conditions

Research might produce treatments of involving transplants with a few, selected types of bacteria tailored to an individual's microbiome.

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials.

One of the projects involves,studying a type of cholesterol that may promote myelin repair.

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of those who received placebo.

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.

Results of a survey show that Black/Indigenous/People of Color or Hispanic patients with Crohn's disease or ulcerative colitis were more likely to report poor symptom control and greater difficulty accessing care from specialists and twice as likely to have an IBD-related emergency department visit compared with White non-Hispanic patients.

Segesterone acetate is a laboratory-made derivative of progesterone, a sex hormone used in many hormonal contraceptives

Study eases some of the concern about Crohn's disease and ulcerative colitis creating undue infection risk.

Roche's drug is one of a number competing to become the first Bruton's kinase inhibitors approved as a treatment for multiple sclerosis.

Entyvio (vedolizumab) and Xeljanz (tofacitinib) are the most commonly studied therapies, according to the Pfizer-sponsored review, and when the two were compared, Xeljanz showed higher remission rates.